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ABSTRACT 
The fields of neuroscience and bone biology have converged following the 
discovery that the nervous system is a key regulator of bone metabolism.  Among the 
different pathways of bone regulation by the nervous system, the Neuropeptide Y 
(NPY) neuronal pathway has been attracting particular attention. Recently, we 
showed that the hypothalamic NPY system also responds to bone injury. However, 
the processes of feedback from injured bone to the NPY neuronal pathway remain 
unknown. Regarding this, the aim of this study was to understand whether the 
factors released in the injured bone microenvironment may cross and/or interact 
with the blood brain barrier (BBB), to reach the central nervous system and 
subsequently modulate the NPYergic hypothalamic response. 
To achieve this goal, as first step, two crucial tools were established for an in 
vitro approach: hypothalamic organotypic cultures and in vitro BBB cultures. 
The hypothalamic organotypic cultures were prepared from 8-days-old 
C57Bl/6 mice brains, based on the air-medium interface culture method. High tissue 
viability and a dense neuronal network were achieved in these cultures. Moreover, 
the stimulation with dexamethasone resulted in an increased NPY expression, 
confirming the responsiveness of the NPY system within the established hypothalamic 
organotypic cultures. 
The in vitro model of the BBB was performed using a brain microvascular 
endothelial cell line (bEnd.3) and primary astrocytes obtained from the cortices of 0 
to 2-day-old Wistar rat pups. The two cell types were cocultured in transwell filters. 
The expression of junctional molecules as claudin-5, ZO-1, occludin and VE-cadherin 
was observed in the bEnd.3 cell-cell contact, confirming the BBB phenotype of these 
endothelial cells. Moreover, the transendothelial electrical resistance (TEER) values 
averaging 71.1 ± 9.4 Ω.cm2 support high integrity of the established barrier, which 
was further confirmed by the low permeability coefficients (Pe) obtained in the 
transendothelial flux test. 
The optimization of the in vitro tools allowed to set-up an experimental 
platform to address the role of the humoral pathway in the feedback from injured 
bone to the hypothalamic NPY system. Hence, the in vitro BBB cultures were treated 
with plasma collected from animals with a bone defect. The resultant conditioned 
medium was used to treat the organotypic cultures and the modulation of the NPY 
system activity was evaluated. The results obtained suggest that molecules within 
the plasma are able to cross and/or interact with the BBB and subsequently increase 
the NPY hypothalamic system activity. However, it was not possible so far to 
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correlate the activation of the NPY system with the presence of a bone defect, as the 
modulation of the NPY system activity appears to be similar in femur-defect and 
sham-operated control conditions. 
Overall, the successful establishment of hypothalamic organotypic cultures 
and an in vitro BBB model, and the combined use of these two systems, allowed the 
establishment of an experimental platform suitable to investigate the role of the 
humoral pathway in the feedback from injured bone to the CNS, specifically to the 
hypothalamic NPY system. Our first results suggest that circulating factors present in 
animals submitted to bone defect are able to modulate the hypothalamic NPY 
system. However, a specific correlation with the presence of a bone defect has not 
yet been proved. 
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RESUMO 
As áreas da neurociência e da biologia do osso convergiram após ser 
descoberto o papel essencial do sistema nervoso na regulação do metabolismo ósseo. 
De entre as diferentes vias de regulação do osso pelo sistema nervoso, a via neuronal 
do Neuropéptido Y (NPY) tem vindo a atrair particular interesse. Estudos recentes 
desenvolvidos no nosso laboratório mostraram que o sistema do NPY ao nível do 
hipotálamo é também ativado em resposta a uma lesão no osso. Contudo, os 
processos de retro-informação entre o osso e a via neuronal do NPY são ainda 
desconhecidos. 
Neste contexto, o objetivo deste trabalho era investigar a capacidade de 
fatores libertados no microambiente do osso com lesão poderem atravessar e/ou 
interagir com a barreira hematoencefálica (BHE), entrando no sistema nervoso 
central (SNC) e, deste modo, modular a resposta do sistema do NPY no hipotálamo. 
Para responder a este objetivo, e para permitir uma abordagem in vitro, duas 
ferramentas cruciais foram estabelecidas, nomeadamente culturas organotípicas de 
hipotálamo e culturas in vitro da BHE. 
As culturas organotípicas de hipotálamo foram realizadas de acordo com o 
método de interface ar-meio, onde foram usados cérebros de ratinhos C57Bl/6. As 
culturas estabelecidas apresentavam uma viabilidade celular elevada, bem como a 
presença de uma densa rede neuronal. Além disso, a estimulação com dexametasona 
aumentou a expressão do NPY, confirmando, assim, a capacidade de resposta do 
sistema NPY nas culturas organotípicas estabelecidas. 
O modelo in vitro da BHE foi estabelecido de acordo com um sistema de 
cocultura de células endoteliais do cérebro (bEnd.3) e astrócitos primários. Neste 
modelo de cocultura, as células endoteliais expressavam moléculas caraterísticas das 
junções impermeáveis e de aderência nas suas zonas de contacto, tais como a 
claudina-5, ZO-1, ocludina e caderina-VE, confirmando o fenótipo de BHE destas 
células. Adicionalmente, os valores da resistência elétrica transendotelial obtidos 
sugerem uma elevada integridade da barreira formada. Esta integridade foi 
confirmada pelos reduzidos coeficientes de permeabilidade obtidos no teste de fluxo 
transendotelial. 
A otimização destas duas técnicas permitiu desenvolver uma plataforma 
experimental para investigar o papel da via humoral na comunicação do osso 
lesionado com o sistema do NPY no hipotálamo. 
As culturas in vitro da BHE foram tratadas com o plasma recolhido de animais 
com defeito ósseo. O meio condicionado resultante então foi usado para tratar as 
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culturas organotípicas de hipotálamo e a modulação da atividade do sistema do NPY 
foi avaliada. Os resultados obtidos sugerem que moléculas presentes no plasma são 
capazes de atravessar e/ou interagir com a BHE e, subsequentemente, aumentar a 
atividade do sistema do NPY no hipotálamo. Contudo, até agora, não foi possível 
estabelecer uma correlação entre a ativação do sistema do NPY e a presença de um 
defeito ósseo, uma vez que a modulação da atividade do sistema do NPY parece ser 
semelhante entre as condições em que estava presente um defeito ósseo e a 
condição controlo em que uma cirurgia foi realizada, mas o osso foi deixado intacto. 
Em suma, o estabelecimento com sucesso das culturas organotípicas de 
hipotálamo e de um modelo in vitro da BHE permitiu, pelo seu uso combinado, 
estabelecer uma plataforma experimental adequada ao estudo do papel da via 
humoral nos mecanismos de retro-informação de um osso com lesão com o SNC, 
neste caso específico, entre o osso e o sistema do NPY no hipotálamo. 
Os primeiros resultados sugerem que fatores em circulação no sangue de 
animais com defeito ósseo são capazes de modular o sistema do NPY no hipotálamo, 
mas a sua estrita correlação com a presença de um defeito ósseo não foi ainda 
comprovada. 
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1.1   BONE AND BONE REMODELLING 
  
Bone is a complex and dynamic living tissue found in vertebrates, organized to 
form, along with cartilage, the skeletal system [1]. Outwardly, bone seems to be a 
static structure but, during its lifespan, it grows and is continuously remodelled [2]. 
Among its major functions, bone protects vital internal organs and bone 
marrow from injury, and gives structural support to the soft tissues, muscles and 
joints, taking advantage of forces generated by muscle contraction to promote body 
movements [3, 4]. Bone is also a mineral reservoir, mainly storing calcium and 
phosphorus [3]. Moreover, the blood cell production occurs in the bone marrow 
present in developing bones of the foetus and in some adult bones [5]. 
Bone is a specialized connective tissue containing different cell types and an 
abundant extracellular matrix (ECM) [4]. The ECM comprehends an inorganic phase, 
mainly composed by calcium phosphate and calcium hydroxide crystals structured as 
hydroxyapatite (Ca10(PO4)6(OH)2) [6], and an organic phase composed by collagen 
type I, proteoglycans and glycoproteins (Fig. 1.1) [3]. 
 
 
Figure 1.1: Bone cells distribution in the extracellular matrix. The dotted region represents the 
newly formed matrix and the dashed lines the calcified matrix. From Junqueira and Carneiro, Basic 
Histology, 2004 [3]. 
 
There are four types of bone cells, namely osteogenic cells, osteoblasts, 
osteocytes and osteoclasts. The osteogenic cells, derived from mesenchyme, have 
the ability to differentiate, under appropriate stimuli, in osteoblasts [4, 7]. The 
osteoblasts synthesize the organic components required for the new ECM formation 
and have a central role in its mineralization. Osteocytes are osteoblasts that have 
become embedded within the bone matrix, and are responsible for sensing 
mechanical strain or its absence and translate it into biochemical signals to 
osteoblasts on bone surface. Osteoclasts, multinucleated giant cells, are the key 
elements for bone resorption [8]. These cells are usually attached to the calcified 
bone surface, leading to the appearance of bone matrix depressions, known by 
Howship’s lacunae (Fig. 1.2) [3, 4, 9–11]. 
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Figure 1.2: Osteoclasts attached to the calcified bone surface. Osteoclastic resorption leading to the 
appearance of bone matrix depressions, the Howship’s lacunae. Adapted from Guyton and Hall,  
Textbook of Medical Physiology, 2011  [11].  
 
Bone is externally and internally recovered by a thin layer of connective 
tissue containing osteogenic cells. The periosteum and endosteum, inner and outer 
layer respectively, synergistically work to ensure bone nutrition and new osteoblasts 
supply [3]. 
A synchronized activity between osteoblasts and osteoclasts is required for a 
balanced formation-resorption cycle, known as bone remodelling (Fig. 1.3) [12], 
[13]. This physiological process is necessary for the substitution of primary bone, the 
infantile bone, with secondary bone, which is mechanically more competent, for the 
removal of ischemic or microfractured bone and for the maintenance of a correct 
calcium homeostasis [14]. 
 
Figure 1.3: Bone remodelling process. Mononuclear osteoclasts differentiated through the 
monocyte/macrophage linage fuse together to form multinucleated giant cells which will migrate to 
the resorption sites. Oppositely, mesenchymal stem cells derived osteoblasts trigger a wave of bone 
formation responsible for the bone mass recovery. From Ferrari-Lacraz and Ferrari, International Bone 
and Mineral Society, 2009 [15]. 
Howship’s lacunae 
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Bone remodelling occurs throughout four major distinct phases: activation, 
resorption, reversal and formation [7, 9]. The activation phase refers to the ability of 
osteocytes to sense mechanical forces, micro-damages in old bone, or the secretion 
of paracrine factors in bone microenvironment [9, 14]. Different inputs deriving from 
osteocytes will activate quiescent osteoblasts, inducing increased RANKL (Receptor 
Activator of Nuclear κB Ligand) expression on their surface. RANKL, in turn, interacts 
with its receptor RANK (Receptor Activator of Nuclear κB), expressed by pre-
osteoclasts, triggering their fusion and differentiation into multinucleated osteoclasts 
[14].  
During the resorption phase, differentiated osteoclasts polarize, tightly 
adhere to bone surface and start the mineralized matrix digestion by the secretion of 
several acids and protein-digesting liposomal enzymes [1].  
On the reversal phase, macrophage-like cells act to remove the undigested 
demineralized collagen matrix, preparing the surface for the following osteoblast-
mediated bone formation [16]. Entering into the formation phase, pre-osteoblasts 
differentiate into osteoblasts, triggering a wave of bone formation [9, 17]. 
 
1.1.1 Regulation of bone remodelling 
It has been commonly accepted that the complex network of interactions 
between osteoblasts and osteoclasts in the bone remodelling cycle is hierarchically 
regulated by endocrine hormones and mechanical stimuli (Fig. 1.4) [18]. 
 
 
Figure 1.4: Regulators of bone remodelling. Osteoblasts are the responsible for bone formation and for 
the mediation of osteoclastogenesis through RANKL system; osteocytes transmit mechanotransduction 
signals to osteoblasts modulating their activity; intermittent release of hormones such as parathyroid 
hormone and insulin-like growth factor-1 and the mechanical stimulation are extrinsic anabolic signals. 
hypothalamic signals transmitted through adrenergic nerves act to inhibit bone formation. From Zaidi, 
Nature Medicine, 2007 [18]. 
 
Several hormones have been described as active interveners of the bone 
metabolism regulation, including parathyroid hormone (PTH), vitamin D3 (1,25 Vit 
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D3), calcitonin and oestrogen [19]. While PTH and 1,25 Vit D3 induce bone resorption 
[19], calcitonin and oestrogen promote bone formation [20, 21]. Other endocrine 
hormones such as growth hormone (GH), follicle stimulating hormone (FSH) and 
thyroid stimulating hormone (TSH) released by the hypothalamic-pituitary axis are 
also involved in bone metabolism regulation. The hormonal regulation of bone mass 
and remodelling is summarized in table 1.1. 
 
 
Hormone Main action Key skeletal effects of global deletion 
Oestrogen Mainly anabolica Oestrogen receptor-α/β: osteoporosis due to low 
formation [22] 
GnRH: osteoporosis due to low formation 
Aromatase: severe osteoporosis due to high resorption 
and low formation [23] 
Testosterone Mainly anabolic Androgen receptor: osteoporosis due to low formation 
[24] 
1,25-(OH)2 vitamin 
D 
Pro-resorptive Vitamin D receptor: rickets rescued by dietary 
intervention 
Thyroid hormone Pro-resorptive in 
excessb; anabolic 
during growth 
Thyroid hormone receptor-α: osteopetrosis due to low 
resorption [25] 
Thyroid hormone receptor-β: osteopetrosis due to low 
resorption [24] 
Parathyroid 
hormone 
Pro-resorptive in 
excess; anabolic 
(intermittent) 
PTH: high density due to low resorption [26] 
PTH/PTHrPR: multiple cartilage defects 
GH and IGF-1 Anabolic GH receptor: osteoporosis 
IGF-1R: osteoporosis 
IGF-1: osteoporosis [27] 
TSH Anti-resorptive TSHR: osteopenia and haploinsufficiency [28] 
FSH Pro-resorptive FSHβ: normal/high density due to low resorption [29] 
FSH receptor: normal density due to low resorption [29] 
or low density due to low formation [30] 
Calcitonin Anti-resorptive Calcitonin: high bone mass [20], [31] 
Calcitonin receptor: bone formation defect [32] 
a Direct osteoclastic effects of oestrogen have been demonstrated in vitro only in limited studies. Importantly, oestrogen also 
regulates skeletal homeostasis in men, with strong correlations between bioavailable oestrogen and bone remodelling. Gender-
independent effects of oestrogen have been shown to be nongenotropic. 
b There is substantial in vitro evidence that thyroid hormones stimulate bone resorption; this has recently been confirmed by 
receptor deletion studies. Both low TSH and high thyroid hormones seem to contribute to bone loss in hyperthyroidism. 
FSH, follicle stimulating hormone; GnRH, gonadotropin-releasing hormone; GH, growth hormone; IGF-1, insulin-like growth factor-1; 
TSH, thyroid stimulating hormone. Adapted from Zaidi, Nature Medicine, 2007 [18]. 
 
Mechanical stimulation is also recognised as an important regulator of bone 
remodelling. A correct bone development requires physical activity, whereas the 
absence of muscular activity, rest or weightlessness accelerates bone resorption [33]. 
In fact, mechanical unloading leads to a compromised bone remodelling cycle, being 
a major cause of osteopenia, a pre-osteoporotic condition [34, 35]. 
Also in the context of bone homeostasis regulation, increasing evidences 
strongly support the involvement of the nervous system. Advances in this domain 
suggest that direct signaling between the central nervous system (CNS) and bone 
occurs through two distinct routes, the neurohumoral and the neural pathway (Fig. 
1.5) [18]. The neurohumoral pathway regulates bone through a set of hormones 
Table 1.1: Systemic hormones regulating bone remodelling and bone mass. 
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released by the hypothalamic-pituitary axis, already described in table 1.1. The 
neural pathway acts through neuronal factors released locally by the peripheral 
fibers innervating bone [36]. 
 
 
Figure 1.5: Bone regulation through the neurohumoral and the neural pathway. The neurohumoral 
pathway regulates bone formation mainly through growth hormone, thyroid-stimulating hormone and 
follicle-stimulating hormone released by the hypothalamic-pituitary axis. The neural pathway regulates 
bone formation by the communication through the sympathetic nervous system. From Zaidi, Nature 
Medicine, 2007 [18].  
 
1.2   NEURAL PATHWAY IN BONE REGULATION 
  
As referred, nervous system has been recently pointed as part of the bunch of 
controllers of bone homeostasis [18]. Nerve fibers with active expression of 
neurotransmitters were shown to be present in bone and receptors for these neural 
ligands were found to be expressed by bone cells [36]. In fact, primary afferent 
sensory and sympathetic nerve fibers are present in periosteum, bone marrow and 
mineralized bone, forming dense parallel networks of processes running along vessels 
and closely associated to bone and bone marrow cells [37, 38].  
Over the years, several neurotransmitters were found to be released locally in 
bone and to regulate the activity of bone cells, including adrenaline, noradrenaline, 
glutamate, calcitonin gene related peptide (CGRP), vasoactive intestinal peptide 
(VIP), substance P (SP) and Neuropeptide Y (NPY) (table 1.2) [36, 39, 40]. 
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Neurotransmitter Receptor Putative intermediary mechanism Putative action 
Glutamate NMDA Ion gated channels  bone remodelling 
Calcitonin gene-
related peptide 
CGRP-R1, CGRP-
R2 
 cAMP  bone formation 
 bone resorption 
Substance P Neurokin-1  cAMP  bone formation 
 bone resorption 
Vasoactive 
intestinal peptide 
VIP-1R, VIP-2R, 
PACAP-R 
 RANK 
 RANKL 
 OPG 
 IL-6 
 bone formation? 
 osteoclast formation 
 osteoclast resorption? 
Catecholamine β-1, α-1 
adrenergic 
receptors 
 cAMP 
 PGE-2 
 bone formation 
 bone resorption 
 
In addition to this local regulation, the mechanisms involved in the control of 
bone homeostasis by the CNS are also being unveiled. The central neural pathway 
started to be envisaged in studies on the leptin system. The first evidences showed 
an increased bone mass phenotype in leptin or leptin receptor deficient animals [41]. 
Subsequent studies allowed to conclude that leptin binds to leptin receptors in 
hypothalamic neurons, increasing the sympathetic neuronal activity and thereby 
increasing the release of norepinephrine (NE) in bone. Binding to the adrenergic 
receptors β2 (Adrb2) on osteoblasts, NE induces a decrease in osteoblasts activity, 
resulting in a weakened bone mass [41–44]. 
Several lines of evidence suggest that leptin acts within the hypothalamus to 
regulate bone remodelling, by controlling the synthesis and/or secretion of 
neuropeptides. In fact, leptin regulates the activity of neurons in the hypothalamic 
arcuate nucleus, by stimulating neurons that express anorexigenic peptides, and 
inhibiting neurons that coexpress the orexigenic NPY [45, 46]. The elevation of NPY 
hypothalamic expression levels observed in animals lacking leptin support the 
existence of a mechanistic link between leptin and NPY in the regulation of bone 
mass [47]. 
In fact, NPY has been shown to be involved in the regulation of bone 
metabolism as a mediator of leptin system [48]. However, the actions of the NPY 
system in bone are more complex than a simple downstream mediator for leptin, 
being now supported an independent role for NPY in bone metabolism regulation [49, 
50].   
 
 
 
cAMP, cyclic adenosine monophosphate; CGRP, calcitonin gene-related peptide; IL-6, interleukin-6; NMDA, N-methyl-D-aspartate; 
OPG, osteoprotegerin; PGE-2, prostaglandin-2; RANK, receptor activator of nuclear κB; RANKL, receptor activator of nuclear κB ligand; 
VIP, vasoactive intestinal peptide;  increase;  decrease. Adapted from Jones et al., The Iowa orthopaedic journal, 2004 [37] 
Table 1.2: Neurotransmitters characterized in bone. 
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1.3  NEUROPEPTIDE Y SYSTEM 
  
The NPY is one of the most evolutionary conserved peptides and is now 
confirmed to be part of the bunch of controllers of bone metabolism [46]. It is a 36-
amino acid polypeptide [51] belonging to the NPY-family along with the endocrinal 
peptide YY (PYY) and the pancreatic polypeptide (PP), which are also 36-amino acid 
peptides [40]. NPY presents a 70% degree of sequence homology shared with PYY and 
50% with PP (Fig. 1.6) [52, 53]. All these members exhibit a PP-fold, which is a 
hairpin-like three-dimensional structure comprising an N-terminal polyproline 
sequence, an amphiphilic α-helix and a type I β-turn [52, 54]. These three elements 
interact among themselves to create a hairpin-like loop that seems to be essential 
for the interaction between NPY-family members and their G-protein coupled 
receptors (GPCRs), the Y receptors [40].  
 
 
Figure 1.6: Amino acid sequence of human NPY, PYY and PP, from the top to the bottom. hPYY and 
hPP share 70% and 50% of the sequence homology with hNPY, respectively. From Sousa, et al., Current 
drug targets, 2009 [52]. 
 
Five NPY-receptors were already identified, namely Y1, Y2, Y4, Y5 and, in 
mouse and rabbit, y6 [41, 55], all belonging to the rhodopsine-like superfamily of 
GPCRs [52]. Despite their varying properties, Y receptors (YRs) use similar signal 
transduction pathways, and their response is mediated through toxin-sensitive Gi and 
Go proteins, with inhibited accumulation of cyclic adenosine monophosphate (cAMP) 
[40]. Intracellular calcium or potassium concentrations can be also influenced by NPY 
receptors, through the mobilization of intracellular calcium stores and through the 
activation/blockage of calcium or potassium channels [40]. Additionally, NPY 
receptor signalling showed to stimulate mitogen-activated protein kinase (MAPK) 
pathways by inducing phosphorylation of the extracellular signal-regulated kinases 
(ERKs) [40]. 
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In equilibrium, NPY behaves as a biologically active PP-fold monomer, based 
on the contact between the N-terminus polyproline helix and the α-helix of the C-
terminus [56]. According to pH levels, temperature or NPY concentration, NPY could 
acquire a dimerized structure, resulting from a hand-shake interaction between two 
NPY molecules in its N-terminus [56]. 
Abundantly present in mammalian nervous system, NPY presents varying 
distributions across the CNS and the PNS [52]. In the CNS, NPY is highly synthesized in 
the hypothalamic region by non-catecholaminergic neurons located in the arcuate 
nucleus (ARC), which project to the paraventricular nucleus (PVN) (Fig. 1.7) [57, 58]. 
Peripherally, NPY is markedly expressed in the sympathetic nervous system, acting 
along with NE and adenosine triphosphate to regulate several body functions [59]. 
 
 
Figure 1.7: NPY expression in the ARC and PVN of the hypothalamus. Adapted from Jhanwar-Uniyal 
et al., Brain research, 1993 [57], Nunemarker et al., Biology of reproduction, 2003 [58], and from 
Luquet et al., Science, 2005 [60].  
 
Its wide expression supports its role in an extensive variety of body functions 
such as body temperature, sexual behaviour, blood pressure, food intake, hormone 
secretion and neural excitability, among others [52]. Evidences have also been 
supporting NPY as an important intervener on several pathology disorders such as 
obesity, memory impairments, alcoholism and depression [52, 59]. 
 
1.3.1 NPY and the regulation of bone mass 
The identification of nerve fibres immunoreactive to NPY in bone tissue 
uncovered a possible regulatory role of this neuropeptide in bone metabolism. 
NPY positive nerve fibres in bone are mostly observed along blood vessels 
[61]. However, NPY is also released by non-neuronal cells commonly associated with 
NPY 
NPY 
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bone metabolism, such as megakaryocytes, endothelial cells, osteoblasts, 
osteoclasts, chondrocytes and on bone marrow stromal cells [62–64]. 
Studies in knockout models provided the first data supporting a putative role 
for NPY in the regulation of bone. Specifically, it was shown that the germline 
deletion of NPY, Y1R or Y2R induced an increase in mice bone mass  [65]. 
Subsequent studies using condition knockout models gave a better 
understanding in the role of the NPY system in bone physiology. In this context, the 
Y2R was demonstrated to regulate bone mass through central NPY neuronal pathways. 
The selective deletion of Y2R on the hypothalamus resulted in a reduced activity of 
the sympathetic neurons and in the NPY levels released in bone, resulting in less 
stimulation of the β2 adrenergic receptors and Y1R present on osteoblasts, leading to 
an increased bone mass phenotype (Fig. 1.8b) [55, 66]. The deletion of Y1R in 
osteoblasts also presented a phenotype of high bone formation, supporting a direct 
interaction between NPY and osteoblasts through the Y1R (Fig. 1.8c). Moreover, the 
specific Y1R deletion on the hypothalamus did not affect bone mass, evidencing a 
peripheral effect of Y1R on bone remodelling [65, 67].  
In summary, whilst the Y2R showed to be able to modulate the osteoblastic 
activity through a centrally mediated mechanism, the Y1R showed to act powerfully 
to inhibit bone production through direct inhibition of osteoblasts activity. 
Therefore, it is now clearly established that the NPY plays a role in the regulation of 
bone mass. 
 
 
Figure 1.8: Pathways for the NPYergic regulation of bone metabolism via Y2 and Y1 receptors. The 
hypothalamic Y2Rs mediate the NPY signaling through the sympathetic neurons in order to inhibit bone 
formation via the Y1R or beta-adrenergic pathways (a). The inhibition of bone formation is reversed either 
by the specific deletion of hypothalamic Y2Rs, subsequently reducing sympathetic neuron activity and NPY 
levels (b), or by osteoblastic Y1R deletion, reducing the NPY mediated down-regulation of osteoblastic 
activity (c). Adapted from Lee and Herzog, Neuropeptides, 2009 [40]. 
a b c 
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1.4  CHALLENGED BONE HOMEOSTASIS 
  
The effective function of an organ depends on an internal process known as 
homeostasis. Homeostasis is the dynamic process that, in response to challenging 
conditions, acts towards the stabilization of the narrow range of body limits that are 
life compatible [68]. Despite the effort of body cells to maintain a balanced activity, 
homeostasis is continuously being disrupted. 
As in almost every physiological system, bone homeostasis is also routinely 
challenged. To bring its internal environment back into balance, bone usually counts 
on the abovementioned remodelling cycle. However, intense and prolonged 
disruptions in the remodelling cycle can prevent bone to recover the equilibrium, 
becoming predisposed to pathological conditions as osteopenia and osteoporosis. 
These conditions promote an increased risk of bone fracture [1]. Additionally, falls or 
other common accidents and repeated strenuous efforts can also lead to the 
occurrence of fractures. 
A fracture is understood as any break in bone. When fractured, bone will 
engage a healing process that comprehends four major steps, namely formation of a 
fracture hematoma, formation a fibrocartilaginous callus, formation of a bony callus 
and bone remodelling (Fig. 1.9) [1]. 
Following a bone fracture, damaged blood vessels release a blood mass that 
surrounds the injured tissue, known as fracture hematoma [1]. Due to the inadequate 
local blood supply, bone cells from the adjacent tissues undergo necrosis, often 
followed by inflammation and swelling [69]. Small blood vessels start to invade the 
fractured area, recruiting immune cells to the injured site that, together with 
osteoclasts, remove the necrotic cells [51]. This inflammatory phase may last up to 
several weeks. Then, a soft callus composed by collagen fibres and fibrocartilage 
starts to arise in the fracture site, bringing together both bone broken ends. The 
formation of the soft callus may take about three weeks [69].  
Following the soft callus formation, osteogenic cells in the nearly healthy 
bone tissue differentiate into osteoblasts. Osteoblasts, in turn, replace the 
fibrocartilage model by spongy bone [1], which are thin columns of lamellae arranged 
in an irregular pattern [3], and the soft callus is then called hard callus. The hard 
callus lasts about three to four months [70]. At the final stage of fracture repair, the 
hard callus undergoes bone remodelling [1] and, in the fracture periphery, spongy 
bone is replaced by compact bone [69], which is organized in concentric lamellae 
containing nerves and blood vessels [3].  
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In the best scenario, there will be no visible trace of fracture after the 
healing process, but only a discrete increase in the adjacent bone thickness [69]. 
 
 
Figure 1.9: Fracture healing process. Briefly, a hematoma is formed (1); small vessels invade the area 
and inflammatory and mesenchymal cells are recruited, giving rise to the soft callus (2); osteogenic 
cells in the nearly healthy bone tissue differentiate into osteoblasts, inducing the formation of 
immature bone tissue, the hard callus (3); the hard callus is gradually remodelled and replaced by 
compact tissue (4). Adapted from Tortora and Derrickson, Principles of Anatomy and Physiology, 2012 
[1]. 
 
Bone homeostatic disruptions, such as imbalances in the remodelling cycle 
and/or the appearance of fractures, trigger the activation of physiological 
mechanisms towards the successful re-establishment of its internal equilibrium [68].   
Increasing interest has been devoted to the understanding of the nervous 
system as a regulatory mechanism over bone repair. The involvement of the NPY 
system, due to its known role as a bone mass regulator, has been attracting 
particular interest, specifically in our laboratory, where several projects have been 
developed in order to understand its role on bone repair. 
 
1.4.1 The role of NPY in bone repair 
The putative involvement of NPY in bone repair is supported by several known 
actions of this neuropeptide. NPY is known to have an angiogenic activity [71]. 
Therefore, NPY may be involved in revascularization of injured bone, an essential 
step for the repair process. Additionally, the NPY has a neurotrophic activity [72] 
and, therefore, may have a role in bone reinnervation, also essential for the success 
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of bone repair. NPY, through its role in the regulation of osteoblastic activity [55], 
may be an important player in the control of bone formation that occurs in late 
stages of the repair process. Moreover, NPY, by the action of the Y1R expressed by 
immune cells, have been demonstrated to have a key role in inflammation [73], an 
important process within bone repair. In fact, previous work developed in our 
laboratory successfully demonstrated that the deletion of the Y1R in mice results in a 
delayed fracture repair, supporting a role for the NPY in bone repair [74]. 
In addition to these putative local role of NPY during bone repair, data also 
obtained in our laboratory from in vivo studies showed that NPY levels were 
increased in the hypothalamus in the early period after bone defect, also suggesting 
the involvement of the central NPY neuronal pathway in response to bone injury 
(Appendix A) [75]. However, the existence of molecular factors locally produced in 
bone that intervene as messengers of bone physiological state to the NPY neuronal 
pathway, remains unclear, particularly in cases of bone fracture. Moreover, the 
question of how these signals reach the processing brain centers in the CNS has not 
been answered yet. 
 
1.4.2 Communication between the peripheral systems and the CNS 
Two major routes have been proposed to explain the communication between 
the peripheral systems and the CNS: a sensory pathway, by the activation of 
peripheral afferent nerves, and/or a humoral pathway, through the bloodstream. The 
CNS is better protected than any other system or organ in the body, since its normal 
functioning requires a very stable internal environment. This stability is provided by 
barriers that isolate the nervous system from blood. 
 
a. Humoral pathway: surpassing the permeability of the barriers protecting 
the CNS 
As referred, the CNS is protected by barriers that represent crucial interfaces 
between the peripheral circulation and the CNS environment [76]. Two major 
barriers limit the blood direct contact with the CNS: the blood-brain barrier (BBB) 
and the blood-cerebrospinal fluid (CSF) barrier (BCSFB) [77]. The BBB regulates the 
exchange of nutrients, waste and immune cells between the circulation and the CNS, 
through an elaborate network of complex junctions that interconnects the 
endothelial cells [78]. The BCSFB is a barrier that separates the cerebrospinal fluid 
and the blood. It is composed by the endothelial cells of the pia mater capillaries 
containing fenestration, the choroid plexus epithelial cells interconnected by tight 
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junctions, and a basal membrane between them. This barrier is more permeable than 
the BBB and, additionally to its barrier function, also has a secretory function  by 
producing the CSF [79]. The functions of the BCSFB are maintained stable by the 
expression of numerous transport systems allowing the directed transport of ions and 
nutrients into the CSF and the removal of toxic agents out of the CSF [80]. 
The BBB comprehends three major elements: the endothelial cells, the 
astrocyte end-feet and the pericytes [81]. 
The endothelial cells are the most prominent cellular elements of the BBB. 
They are characterized by the presence of specific cellular interconnections in a 
junctional complex formed by tight and adherens junctions (Fig. 1.10) [81]. 
The tight junctions present within the endothelial cells form a diffusion 
barrier that selectively excludes most blood-borne substances from entering the 
brain [81]. They regulate the movement of ions and solutes in-between cells [82], 
forcing most cellular traffic to take a transcellular route across the endothelial cells, 
rather than moving paracellularly through the junctions, as in most endothelia [83]. 
Additionally, the tight junctions are responsible for the separation of the apical and 
the basolateral domains of the membrane, contributing to the polarization of the cell 
[83]. The molecular components of the tight junctions are transmembrane proteins, 
including occludin, claudin and junction adhesion molecules, and a number of 
cytoplasmic accessory proteins including zonula ocludens (ZO) -1, ZO-2 and ZO-3 
[84]. 
The adherens junctions initiate cell-cell contacts and mediate the maturation 
and maintenance of the intercellular contact by trans-pairing between cadherins on 
opposing cells [82]. The transmembrane proteins of the adherens junctions are the 
cadherins, in the BBB mainly the vascular endothelial (VE) –cadherin, which are 
linked to the cytoskeleton through catenins [83]. The adherens junctions are 
essential for the adequate development of the tight junctions. 
The tightness of the endothelial cells along with the absence of fenestrations, 
turn the BBB a high-restrictive structure to potentially toxic substances from the 
blood to the brain [83]. 
The astrocytes and their characteristic end-feet cover a significant part of the 
endothelial cells and are known to play an essential role in the integrity of the BBB 
[79]. Moreover, the astrocytes also contribute to the restrictive permeability 
properties of this barrier since they are capable to induce a BBB phenotype in the 
endothelial cells [85], specifically through the potentiation of the development of 
tighter tight junctions [86, 87]. 
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Figure 1.10: Main BBB characteristic junctional molecules. Schematic representation of protein 
interaction associated with tight and adherens junctions at the BBB. Occludin, claudin and junction 
adhesion molecules are transmembrane proteins, and ZO-1, ZO-2 and ZO-3, among others, are 
cytoplasmatic proteins. Claudin and occludin are linked to actins through these cytoplasmatic proteins. 
Adapted from Ballabh et al., Neurobiology of disease, 2004 [81].  
 
The role of pericytes in the BBB is yet to be properly clarified. Currently, it is 
accepted that pericytes appear to play a role in the formation, structural integrity 
and differentiation of the blood vessels, and may also have a role in the formation of 
the endothelial tight junctions [88–91]. 
The selective permeability of the BBB is of particular clinical interest since it 
protects the delicate and vulnerable environment of the brain. However, the BBB can 
be transposed through five distinct mechanisms (Fig. 1.11). Despite the 
interendothelial restrictive junctions, small water soluble compounds are able to 
cross the BBB through the paracellular route [83]. A transcellular pathway is made 
possible by the large surface area of the cytoplasmatic membranes of the 
endothelium, where small lipophilic agents can cross through diffusion [79]. The 
cerebral endothelium also displays proteins that act as carriers for molecules as 
glucose, amino acids and nucleosides [92]. Some proteins are also able to cross the 
BBB through receptor-mediated endocytosis and transcytosis, such as it is described 
for insulin and transferrin [83]. Lastly, some large substances can be transported 
across the BBB by adsorptive-mediated endocytosis/transcytosis, as the case of 
albumin [79]. 
The protection of the CNS conferred by the BBB, through a highly controlled 
molecule transport from blood to the CNS, turns the BBB one of the most important 
components of the body. 
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Figure 1.11: Cells, junction complexes and molecular traffic through the BBB. Schematic 
representation of the endothelial cells, the associated astrocyte end-feet, and the transport machinery 
at the BBB. Small lipid-soluble substrates can diffuse across the membrane; proteins in the 
endothelium can act as efflux transporters for small molecules; small hydrophilic molecules can be 
transported via paracellular route, crossing the restrictive tight junctions; large molecules can be 
transported through receptor-mediated endocytosis/transcytosis through vesicular trafficking, as 
insulin or transferrin; other large proteins can cross the BBB by adsorptive-mediated 
endocytosis/transcytosis, as albumin. Adherens junctions allow the intercommunication within the 
endothelial cells of the BBB. From Omidi and Barar, BioImpacts, 2012 [92]. 
 
Supported by the increasing interest that has been devoted to the humoral 
pathway in the communication between the periphery and the CNS, in this study we 
hypothesized that factors released in the injured bone microenvironment may signal 
to the CNS and modulate the hypothalamic NPY system, through an humoral 
pathway, namely by crossing and/or interacting with the BBB. 
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1.5 AIM 
  
Among the different identified neuronal pathways that have a regulatory role 
in bone homeostasis, the NPY system has been recently attracting particular 
attention. Data obtained in our laboratory from in vivo studies extended the previous 
knowledge on the role of NPY in bone homeostasis and showed that the hypothalamic 
NPY system also responds to a bone injury. Despite this, nothing is known regarding 
the communication between and injured bone and the hypothalamic NPY system. 
Therefore, in order to clarify the role of the humoral pathway in the 
communication between injured bone and the hypothalamic NPY system, the aim of 
this study was to determine whether the systemic factors released after bone injury 
may cross and/or interact with the BBB and modulate the NPY hypothalamic 
response. 
 
To achieve this goal, the following specific objectives were defined: 
- Establishment of crucial tools for an in vitro approach: the hypothalamic 
organotypic cultures and the in vitro blood-brain barrier cultures; 
- Assessment of the hypothalamic NPY expression levels in response to 
circulating factors released after bone injury. 
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2.1 MATERIALS 
  
The following tables include the reagents used for each step of the 
experimental procedure, the catalogue references and the respective suppliers. 
 
2.1.1 Hypothalamic organotypic cultures 
 
Table 2.1: Hypothalamic organotypic cultures reagents 
REAGENT REFERENCE / SUPPLIER 
D-(+)-Glucose G6152 Sigma Aldrich® 
Dexamethasone D4902 Sigma Aldrich® 
Gey’s Balanced Salt Solution G9779 Sigma Aldrich® 
Horse Serum, heat inactivated 26050-088 Gibco® (Invitrogen) 
Hank’s Balanced Salt Solution (HBSS) H9269 Sigma Aldrich® 
L-Glutamine 25030-024 Gibco® (Invitrogen) 
Neurobasal® Medium 21103-049 Gibco® (Invitrogen) 
Opti-MEM®, Reduced Serum Medium 11058-021 Gibco® (Invitrogen) 
Penicillin/Streptomycin (P/S) 15140-122 Gibco® (Invitrogen) 
Phosphate Buffered Saline (PBS): 
Sodium Chloride (NaCl) 
Potassium Chloride (KCl) 
Sodium Phosphate, Dibasic (Na2HPO4) 
Potassium Phosphate Monobasic (KH2PO4) 
 
106404 EMSURE® (Merck Millipore) 
P8041 Sigma-Aldrich® 
106586 EMSURE® (Merck Millipore) 
P5655 Sigma-Aldrich® 
 
Table 2.2: Live/dead assay reagents 
REAGENT REFERENCE / SUPPLIER 
Calcein AM C1430 Molecular Probes® (Invitrogen) 
Phosphate Buffered Saline (PBS): 
Sodium Chloride (NaCl) 
Potassium Chloride (KCl) 
Sodium Phosphate, Dibasic (Na2HPO4) 
Potassium Phosphate Monobasic (KH2PO4) 
 
106404 EMSURE® (Merck Millipore) 
P8041 Sigma-Aldrich® 
106586 EMSURE® (Merck Millipore) 
P5655 Sigma-Aldrich® 
Propidium iodide (PI) P4170 Sigma Aldrich® 
  
 
 
 
 
 
 
22 Materials and methods 
 
Master in Biomedical Engineering 2013/2014 
 
Table 2.3: Immunohistochemistry reagents 
REAGENT REFERENCE / SUPPLIER 
4′,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) 
D9542 Sigma Aldrich® 
Alexa Fluor 568® Rabbit Anti-Mouse A11061 Molecular Probes® (Invitrogen) 
Alexa Fluor® 488 Goat Anti-Rabbit A-11008 Molecular Probes® (Invitrogen) 
Anti-200 kD Neurofilament Heavy (NF200) ab78158 Abcam® 
Anti-Iba1 ab5076 Abcam® 
Bovine Serum Albumin (BSA) A9418 Sigma Aldrich® 
Fetal Bovine Serum (FBS) 10270-106 Gibco® (Invitrogen) 
Fluoroshield™ F6182 Sigma Aldrich® 
Normal Goat Serum (NGS) ab7481 Abcam® 
Paraformaldehyde (PFA) 158127 Sigma Aldrich® 
Phosphate Buffered Saline (PBS): 
Sodium Chloride (NaCl) 
Potassium Chloride (KCl) 
Sodium Phosphate, Dibasic (Na2HPO4) 
Potassium Phosphate Monobasic (KH2PO4) 
 
106404 EMSURE® (Merck Millipore) 
P8041 Sigma-Aldrich® 
106586 EMSURE® (Merck Millipore) 
P5655 Sigma-Aldrich® 
Rabbit Anti-Glial Fibrillary Acidic Protein 
(GFAP) 
Z0334 Dako (Labometer) 
Rabbit Anti-Neuropeptide Y N9528 Sigma Aldrich® 
Triton X-100 17-1315-01 Amersham Biosciences (VWR) 
 
2.1.2 In vitro BBB cultures 
 
Table 2.4: In vitro BBB cultures reagents 
REAGENT REFERENCE / SUPPLIER 
Collagen from rat tail C7661 Sigma Aldrich® 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
41965-039 Gibco® (Invitrogen) 
Fetal Bovine Serum (FBS) 10270-106 Gibco® (Invitrogen) 
Hydrobromic acid solution ≥33% in glacial 
acetic acid 
02206 Riedel-de Haën (Sigma-Aldrich®) 
Penicillin/Streptomycin (P/S) 15140-122 Gibco® (Invitrogen) 
Phosphate Buffered Saline (PBS): 
Sodium Chloride (NaCl) 
Potassium Chloride (KCl) 
Sodium Phosphate, Dibasic (Na2HPO4) 
Potassium Phosphate Monobasic (KH2PO4) 
 
106404 EMSURE® (Merck Millipore) 
P8041 Sigma-Aldrich® 
106586 EMSURE® (Merck Millipore) 
P5655 Sigma-Aldrich® 
Trypan Blue solution T-8154 Sigma-Aldrich® 
Trypsin T-0646 Sigma-Aldrich® 
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Table 2.5: Transendothelial flux reagents 
REAGENT REFERENCE / SUPPLIER 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
41965-039 Gibco® (Invitrogen) 
Fluorescein sodium salt F6377 Sigma-Aldrich® 
Hank’s Balanced Salt Solution (HBSS) 14025-092 Gibco® (Invitrogen) 
 
Table 2.6: Immunocytochemistry reagents 
REAGENT REFERENCE / SUPPLIER 
4′,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) 
D9542 Sigma Aldrich® 
Alexa Fluor 488® Phalloidin A12379 Molecular Probes® (Invitrogen) 
Alexa Fluor 568® Goat Anti-Rabbit A11011 Molecular Probes® (Invitrogen) 
Bovine Serum Albumine (BSA) A9418 Sigma Aldrich® 
Horse Serum, heat inactivated 26050-088 Gibco® (Invitrogen) 
Fetal Bovine Serum (FBS) 10270-106 Gibco® (Invitrogen) 
Fluoroshield™ F6182 Sigma Aldrich® 
Mouse Anti-Claudin-5 conjugated with 
Alexa Fluor® 488  
352588 Molecular Probes® (Invitrogen) 
Normal Goat Serum (NGS) ab7481 Abcam® 
Rabbit Anti-Occludin  71-1500 Novex® (Invitrogen) 
Paraformaldehyde (PFA) 158127 Sigma Aldrich® 
Phosphate Buffered Saline (PBS): 
Sodium Chloride (NaCl) 
Potassium Chloride (KCl) 
Sodium Phosphate, Dibasic (Na2HPO4) 
Potassium Phosphate Monobasic (KH2PO4) 
 
106404 EMSURE® (Merck Millipore) 
P8041 Sigma-Aldrich® 
106586 EMSURE® (Merck Millipore) 
P5655 Sigma-Aldrich® 
Rabbit Anti-Glial Fibrillary Acidic Protein 
(GFAP) 
Z0334 Dako (Labometer) 
Rabbit Anti-VE-Cadherin (CD144) V1514 Sigma Aldrich® 
Rabbit Anti-ZO-1 61-7300  Novex® (Invitrogen) 
Triton X-100 17-1315-01 Amersham Biosciences (VWR) 
Tween® 20 A4974.0250 AppliChem (VWR) 
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2.2 MOUSE HYPOTHALAMIC ORGANOTYPIC CULTURES 
  
In this study all animal procedures were approved by the Portuguese Agency 
for Animal Welfare (General Board of Veterinary Medicine in compliance with the 
Institutional Guidelines and the European Convention), and performed only by 
researchers graded C by FELASA. All efforts were made to minimize the number of 
animals used and their suffering.  
 
2.2.1 Organotypic slice cultures 
Hypothalamic organotypic slice cultures were prepared according to the air-
medium interface culture method adapted from Stoppini et al. [93] and Gähwiler et 
al. [94], as described for hippocampal organotypic cultures by Gonçalves et al. [95]. 
Eight-day-old wildtype C57Bl/6 mice were sacrificed by decapitation. Under 
sterile conditions, brains were rapidly removed (Fig. 2.1a) and sectioned into 
transverse slices on a McIlwain tissue chopper (Fig. 2.1b, c and d) (Mickle Laboratory 
Engineering Ltd, Surrey, UK). During the optimization process, slices thickness 
ranging between 250 and 350 μm were tested. Higher tissue viability was presented 
by 250 μm-thick slices. Therefore, this thickness was selected to be used in the 
experiment. Slices were transferred (Fig. 2.1e) and gently separated in ice-cold 
Gey’s balanced salt solution with 25 mM D-glucose and 0.01% P/S (Fig. 2.1f). 
Hypothalamic sections including the ARC and the PVN were selected, trimmed 
laterally by the ARC and dorsally by the PVN (Fig. 2.1g), and individually placed into 
a porous (0.4-µm) and sterile insert membrane (Fig. 2.1h) (Millipore, Madrid, Spain), 
in a total of six slices per insert. The inserts were transferred to a six-well culture 
plate (Fig. 2.1i) previously prepared with 1 mL culture medium composed by 50% 
Opti-MEM®, 25% heat-inactivated horse serum, 25% HBSS and 0.01% P/S, 
supplemented with D-glucose to a final concentration of 25 mM. Cultures were 
maintained in a humidified 5% CO2 atmosphere at 37 ºC for 15 days. Every two days, 
half culture medium was removed and replaced by fresh medium. 
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Figure 2.1: Hypothalamic organotypic cultures experimental procedure. Brains (a) were removed 
from 8-days-old C57Bl/6 mice, taken to McIlwain tissue chopper (b) and sectioned into 250 µm slices (c, 
d). Slices were transferred (e), and separated in dissection medium (f). Hypothalamic region was 
dissected (g), placed into a porous insert membrane (h) and transferred to a 6-well plate (i) with Opti-
MEM
®
 culture medium.  
 
2.2.2 Cell viability assessment 
Levels of metabolically healthy cells and dead cells were examined using 
Calcein AM and PI. Calcein AM penetrates the living cells and is metabolized in the 
cytoplasm [96]. The resultant green fluorescent product allows the identification of 
the viable cells under appropriate illumination. PI fails the penetration of the healthy 
plasmatic membrane, crossing otherwise the compromised membrane of the dying 
cells. It is a nucleic acids stoichiometric binder that interacts with the dead cells 
nuclei, emitting red fluorescence under appropriate illumination [97]. 
After washing with 0.01 M PBS, pH 7.4, slices were incubated with Calcein AM 
in 0.01 M PBS for 30 min at 37 ºC. Calcein AM was washed out and slices were 
incubated with PI for 10 min at 37 ºC. Calcein AM and PI staining was recorded by 
confocal microscopy (Leica TSC SP5II, Leica Microsystems, Wetzlar, Germany). The 
live and dead cells were counted using the ImageJ software (ImageJ 1.48 for 
Windows, Maryland, USA). 
 
2.2.3 Immunostaining of neurons, astrocytes and microglia 
To confirm the presence of neurons within the viable slices of the 
hypothalamic organotypic cultures, an immunostaining for NF200, a neuronal marker, 
was performed. In parallel, the presence of astrocytes and microglia was also 
assessed by immunostaining for GFAP and Iba-1, respectively. 
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Hypothalamic slice cultures were fixed with ice-cold 4% PFA in 0.01 M PBS at 
ice-cold temperature for 30 min. After washing with 0.01 M PBS, non-specific 
antibody binding was blocked with 10% FBS and 1% BSA, simultaneously with cells 
permeabilization with 0.02% Triton X-100 in 0.01 M PBS at RT for 60 min. Slices were 
incubated with rabbit anti-NF200 (1:1000), rabbit anti-GFAP (1:500), or rabbit anti-
Iba-1 (1:500) antibodies diluted in blocking solution, O/N at 4 ºC. After washout the 
primary antibody, slices were incubated with Alexa Fluor® 568 goat anti-rabbit 
(1:1000; for NF200) and with Alexa Fluor® 488 goat anti-rabbit (1:1000; for GFAP and 
Iba-1) antibodies at RT for 60 min, protected from light. 
For nucleus counterstaining, slices were incubated with 0.1 μg/mL DAPI in 0.1 
M PBS, for 5 min at RT. Finally, slices were washed in 0.1 M PBS, assembled in 
Fluoroshield™ mounting medium, and observed at Confocal Leica TSC SP5II (Leica 
Microsystems, Wetzlar, Germany). 
 
2.2.4 Assessment of NPY system activity 
To evaluate the ability of neuronal cells from the ARC to express NPY, slices 
were treated with dexamethasone, a glucocorticoid described to stimulate the 
hypothalamic NPYergic activity [98]. 
15 days after culture, slices were incubated with 10-7 M dexamethasone [98] 
in Neurobasal medium supplemented with 1 mM L-glutamine and 0.01% P/S  for 24 h 
in a 37 ºC, 5% CO2 air incubator. NPY expression was then evaluated by 
immunohistochemistry. 
Briefly, slices were fixed with ice-cold 4% PFA in 0.01 M PBS at ice-cold 
temperature for 30 min. Simultaneously, non-specific antibody binding was blocked 
and cells were permeabilized with 10% NGS and 0.3% Triton X-100, respectively, in 
0.01 M PBS at RT for 60 min, and incubated with goat anti-NPY antibody (1:6000) in 
blocking and permeabilization solution, O/N at 4 ºC. Afterwards, slices were washed 
and incubated with Alexa Fluor 568® goat anti-rabbit (1:200) at RT for 120 min, 
protected from light. 
Nuclei counterstaining was performed as described in section 2.2.3, and slices 
were observed at confocal microscope (Leica TSC SP5II, Leica Microsystems, Wetzlar, 
Germany). 
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2.3 IN VITRO BLOOD-BRAIN BARRIER CULTURES 
  
2.3.1 bEnd.3 cell line 
Immortalized mouse endothelial cell line, bEnd.3, was acquired from ATCC 
(American Type Culture Collection) (catalogue number CRL-2299), were cultured in 
DMEM+L-glutamine (with 1.5 g/L of NaCO3) supplemented with 10% FBS, 1% pyruvate 
and 1% P/S. Cells were maintained in a humidified 5% CO2 atmosphere at 37 ºC. The 
medium was changed every 2-3 days. 
 
2.3.2 Rat primary astrocytes isolation 
Astrocytes were obtained from the cortices of 0 to 2-day-old Wistar rat pups. 
The animals were euthanized and, under aseptic conditions, brains were removed 
and rinsed in 0.01 M PBS. The meninges-free cortical tissue was isolated, minced, 
and digested in trypsin for 30 min at 37ºC. The digested tissue was homogenized in 
DMEM supplemented with 10% FBS and 1% P/S. The brain homogenate was pelleted by 
centrifugation at 1200 rpm, for 5 min at 4 ºC. The supernatant was discarded and the 
pellet was re-suspended in complete DMEM. The remaining astrocytes were 
transferred to a T75 culture flask for approximately 10 days, with medium change 
every 2-3 days.  
 
2.3.3 bEnd.3 cells and astrocytes harvesting and sub-culturing 
For the cell culture maintenance, both bEnd.3 cells and astrocytes were 
harvested once or twice a week. Briefly, the cell monolayer was washed with pre-
warmed 0.01 M PBS. Trypsin solution was added, and the cells were maintained in a 
humidified 5% CO2 atmosphere at 37 ºC, for 5 to 10 min. The enzymatic reaction was 
stopped by adding culture medium. The cell suspension was transferred to a new-
labelled flask containing pre-warmed medium. Cells were maintained in the 
incubator at 37 ºC. 
 
2.3.4 In vitro BBB model 
In order to mimic a functional model of the BBB, a coculture system was 
performed, using primary astrocytes and bEnd.3 cells cultured in a non-contact 
system through the use of transwell filters, as described by Li et al. [84]. 
Collagen type IV (0.1% w/v) was used as the basement membrane substitute 
for the in vitro BBB model. Collagen was diluted in 0.1 M CH3COOH solution to a 
concentration of 10 mg/mL. Transwell filters (0.4 µm pore size, 24-well; BD 
Biosciences, San Jose, CA, USA) were reversed and 30 µL of the collagen solution was 
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Seed astrocytes onto 
the abluminal side Adhere for 6-8 hours Coat transwell filter 
Grow for 2 days 
Seed bEnd.3 cells 
onto the luminal 
side 
Coculture for 11 days 
added to the abluminal side of each filter. The filters were maintained for 8 h at 4 
ºC. The filters were reversed and placed into a 24 transwell plate. 30 µL of collagen 
solution were added to the luminal side of the filters and the plate was placed at 4 
ºC for 8 h. The collagen coated transwell filters were maintained in a sterile hood 
and allowed to air dry O/N. 
Prior to cell seeding, the collagen coated transwell filters (Fig. 2.2a) were 
inverted. The astrocytes were added to their abluminal side at a density of 5 x 104 
cells per cm2 (Fig. 2.2b). After 6-8 h of adhesion (Fig. 2.2c), the inserts were flipped 
back and the astrocytes were let to grow in DMEM supplemented with 10% FBS and 1% 
P/S for 2 days (Fig. 2.2d). Subsequently, bEnd.3 cells were seeded onto the luminal 
side of the filters at a density of 2 x 105 cells per cm2 (Fig. 2.2e). 
As control, astrocytes and bEnd.3 cells monocultures were performed in 
transwell filters, following the procedure described for the coculture. Both coculture 
and monoculture were maintained for 11 days (Fig. 2.2f), with half medium change 
of both abluminal and luminal sides of the transwell filters every day. 
 
Figure 2.2: In vitro BBB cultures experimental procedure. Transwell filters (0.4 µm porous) were 
coated with collagen type IV to mimic the basement membrane (a). Astrocytes were seeded onto the 
abluminal side of the filters at a density of 5 x 104 cells per cm2 (b) and allowed to adhere from 6 to 8 
h (c).  The filters were flipped back and the astrocytes were cultured for 2 days in DMEM supplemented 
with 10% FBS and 1% P/S (d). At the end of the second day, bEnd.3 cells were seeded onto the luminal 
side of the filters at a density of 2 x 105 per cm2 (e). The coculture was maintained for 11 days (f), with 
half medium changed every day. Adapted from Li et al. [84]. 
 
2.3.5 bEnd.3 cells and astrocytes phenotype 
a. Cell morphology 
The ability of astrocytes and bEnd.3 cells to maintain their morphology in this 
coculture system was assessed through cytoskeleton staining. 
Materials and methods 29 
 
Master in Biomedical Engineering 2013/2014 
 
Astrocytes and bEnd.3 cells, grown in collagen type IV coated transwell filters 
for 11 days as described above, were fixed with 2% PFA for 10 min at 37 ºC, and post-
fixed with 4% PFA and 4% sucrose 0.01 M PBS  in the same conditions. After washing 
with 0.01 M PBS cells were permeabilized with 0.25% Triton X-100 in 0.01 M PBS for 5 
min at RT. Cells were washed with 0.01 M PBS, and non-specific protein interactions 
were blocked with 1% BSA in 0.01 M PBS  for 30 min at RT. After washout the blocking 
solution, cells were incubated with Alexa Fluor® 488 Phalloidin for 60 min at RT.  
The nuclei were counterstained by incubation with 0.1 μg/mL DAPI in 0.1 M 
PBS, for 5 min at RT. The cell monolayers were washed with 0.1 M PBS, assembled in 
Fluoroshield™ mounting medium, and observed at Zeiss AxioImager Z1 (Carl Zeiss, 
Germany). 
 
b. Astrocytes expression of GFAP 
The astrocytes ability to maintain their phenotype in this coculture system 
was assessed by immunocytochemistry. After 11 days in culture, cells were fixed in 
4% PFA for 15 min, washed  in 0.1 M PBS, permeabilized with 0.2% Triton X-100 in 0.1 
M PBS for 10 min at ice-cold temperature, washed in 0.1 M PBS and non-specific 
protein interactions were blocked with 5% horse serum and 3% BSA. The astrocytes 
were incubated with rabbit anti-GFAP antibody (1:500) diluted in 1% horse serum, 1% 
BSA and 0.05% Tween 20 in PBS, O/N at 4 ºC. Afterwards, the astrocytes were washed 
and incubated with Alexa Fluor® 568 goat anti-rabbit antibody (1:1000), diluted in the 
same solution, for 1h at RT. 
Nuclei counterstaining was performed as described in section 2.3.5a, and cells 
were observed at observed at Zeiss AxioImager Z1 (Carl Zeiss, Germany). 
 
c. Endothelial expression of junctional proteins 
To assess the ability of the endothelial cells to develop and maintain a BBB 
phenotype, the presence of tight and adherens junctions was assessed by 
immunocytochemistry. The endothelial cells were fixed in 4% PFA. After washing in 
0.1 M PBS, cells were permeabilized with 0.2% Triton X-100 in 0.1 M  PBS for 10 min 
at RT (for claudin-5), with 0.05% Triton X-100 in 0.1 M PBS for 10 min at RT (for ZO-1 
and VE-cadherin), or with 0.05% Triton X-100 in 0.1 M PBS for 5 min at ice-cold 
temperature (for occludin). After wash in 0.1 M PBS, non-specific antibody binding 
was blocked with 10% FBS (for claudin-5) or 10% NGS (for ZO-1 and VE-cadherin) in 
0.1 M PBS for 30 min at RT. The cells were incubated with mouse anti-claudin-5, 
rabbit anti-ZO-1, rabbit anti-occludin, or rabbit anti-VE-cadherin antibodies (1:100) 
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O/N, at 4 ºC. After washout the primary antibody in 0.1 M PBS, cells were incubated 
with Alexa Fluor® 568 goat anti-rabbit (1:1000) for 1h at RT. 
Nuclei counterstaining was performed as described in section 2.3.5a, and cells 
were observed at Zeiss AxioImager Z1 (Carl Zeiss, Germany). 
 
2.3.6 Assessment of the in vitro BBB integrity 
Healthy and confluent cell monolayers with developed tight and adherens 
junctions will possess high transendothelial electrical resistance (TEER) values and 
reduced endothelial fenestrae [76]. 
In this study, the integrity of the in vitro model of the BBB was assessed 
through the TEER measurement, which is an indicator of ion conductance across the 
cell monolayer [99]. In parallel, the evaluation of non-specific paracellular 
permeability to small molecules was assessed through the transendothelial flux [76, 
100]. 
 
a. TEER measurement 
bEnd.3 cells and astrocytes cocultured on transwell filters in 24-well plates 
were removed from the incubator and allowed to equilibrate to RT for 10 min. TEER 
values were measured using a Millicell® ERS-2 volt-ohm-meter with STX01 electrodes 
(Millipore, MA, USA), schematically represented in figure 2.3. To calculate TEER and 
report the values to Ω x cm2, the TEER of the blank transwell filters (collagen type 
IV-coated inserts without cells) was subtracted to the TEER of each well of coculture, 
and this value was multiplied by the surface area of the insert (0.33 cm2). The values 
of TEER in bEnd.3 cells monoculture were also collected to serve as control, namely 
to investigate the role of the astrocytes in the BBB establishment. 
 
 
Figure 2.3: Schematic representation of the TEER measurement. TEER values of the bEnd.3 cells and 
astrocytes coculture on collagen type IV coated transwell filters were monitored. As control, TEER 
values of the bEnd.3 cells monoculture were also collected. 
 
 Ω 
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b. Transendothelial flux 
Transendothelial flux test was adapted from a protocol described by Watson 
and co-workers [76]. Briefly, fluorescein sodium salt stock solution (376 Da) was 
prepared in HBSS buffer at a final concentration of 0.1 mg/ml. bEnd.3 cells and 
astrocytes were seeded onto transwell filters as described, and cocultured for 11 
days in vitro. As control, bEnd.3 cells monocultures were also tested. 
For this experiment, all media was removed both from luminal and abluminal 
sides of the insert membrane and the transwell filters were washed with pre-warmed 
to 37 ºC HBSS. At time point 0 min, 100 µL of a 100 µg/ml fluorescein sodium salt 
solution was added to the luminal side of the filters, which were then transferred to 
a new 24-well plate, previously prepared with 600 µL of HBSS pre-warmed to 37 ºC. 
Cocultured, monocultured and cell-free inserts (collagen type IV coated) were used 
in triplicate. The plates were placed in an orbital shaker and incubated at 37 ºC, 25 
rpm. In order to prevent back diffusion of fluorescein sodium salt into the bottom 
chamber, the inserts were moved into a fresh 24-well plate containing 600 µL of pre-
warmed HBSS at each time point. Samples were collected at 15, 30, 45 and 60 min. 
At the end of the experiment, the concentration of the fluorescent compound 
accumulated in the bottom chamber of the filter was calculated by transferring 100 
µL of each sample to a black walled-96 well plate (Greiner Bio-one, Frickenhausen, 
Germany) and measuring with a fluorometer microplate reader (BioTek instruments, 
USA), with excitation wavelength of 460 nm2 and emission wavelength of 515 nm2. 
Concentrations were calculated using standard curves generated from the 
fluorescein sodium salt stock solution. Permeability coefficients (Pe) of the 
cocultured and monocultured were calculated as previously described [101–104]. 
Briefly, the cleared volume across the cocultured, monocultured and cell-free inserts 
was calculated using the following equation: 
 
𝐶𝑙𝑒𝑎𝑟𝑒𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 (𝜇𝐿) =  
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑎𝑏𝑙𝑢𝑚𝑖𝑛𝑎𝑙  × 𝑉𝑜𝑙𝑢𝑚𝑒𝑎𝑏𝑙𝑢𝑚𝑖𝑛𝑎𝑙
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑙𝑢𝑚𝑖𝑛𝑎𝑙
 
 
The average cleared volumes were plotted versus time in min. Clearance 
slopes for the cell-free filters (PSfilter) and the filters with cells (PScells+filter) were 
calculated using linear regression analysis and used to obtain a permeability product 
value for the cells monolayer alone (PScells): 
 
1
𝑃𝑆𝑐𝑒𝑙𝑙𝑠
=  
1
𝑃𝑆𝑐𝑒𝑙𝑙𝑠+𝑓𝑖𝑙𝑡𝑒𝑟
−  
1
𝑃𝑆𝑓𝑖𝑙𝑡𝑒𝑟
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Pe across the cells in coculture and monoculture were finally derived by dividing the 
PScells value by the surface area of the cell culture insert, 0.33cm
2. Data are 
presented with units of 10-6 cm/sec.  
 
2.4 HYPOTHALAMIC NPYERGIC RESPONSE TO SYSTEMIC FACTORS RELEASED 
AFTER BONE INJURY 
  
2.4.1 Surgery procedure and blood sampling 
Plasma was obtained at day 1, 3 and 7 post-surgery from femur-defect and 
sham-operated animals. Briefly, three months old C57BL/6 male mice provided by 
the animal house of IBMC/INEB Associate Laboratory were under 
Ketamine/Medetomidine anaesthesia (i.p. injection of Ketamine/Medetomidine  
(Ketamine (Clorketam 1000, Vetoquinol S.A., Lure, France); Medetomidine 
(Dexdomitor® , Orion Pharma, Espoo, Finland)). A 1 cm skin incision along the upper 
leg was performed, and muscle carefully retracted, exposing the femur. A hole was 
performed in the femur diaphysis by using a 23G needle. After wound closure, 
analgesia was provided by the administration of 1 µg/g body weight of butorfanol 
(Butador®, Richer Pharma AG, Wels, Austria) during 5 days. The sham-operated 
animals underwent the same surgical procedure but the femurs were left intact. 
Trunk blood was collected at the defined time points in lithium heparin cover 
tubes and centrifuged at 1600 g for 15 min. The obtained plasma was kept at -80 ºC 
until analyses. Plasma obtained from non-operated animals was also collected and 
used as control. This experiment was performed by Cecília Juliana Alves in the scope 
of her post-doc project. 
For the purpose of the present study, experiments have been performed using 
plasma collected at day 1 post-surgery, since in vivo studies performed by our team 
showed a modulation of the NPY expression in the hypothalamus at this time point, 
which seems to be specific for injured bone animals. 
  
2.4.2 NPY system activity in hypothalamic organotypic cultures treated 
with conditioned medium from the in vitro BBB cultures 
To address the ability of systemic factors to affect the NPY system activity in 
hypothalamic organotypic cultures after crossing and/or interacting with the BBB, 
plasma obtained as described in the section 2.4.1a was used in the BBB cultures. The 
resultant conditioned medium was used to treat the organotypic cultures and the 
NPY system activity was evaluated (Fig. 2.4). 
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Figure 2.4: Schematic representation of the experimental set-up. Plasma collected at day 1 post-
surgery from animals with femur-defect was used in the in vitro BBB cultures, and the resulting 
conditioned medium was used to treat the hypothalamic organotypic cultures. 
 
a. Hypothalamic slices incubated with DMEM 
The ability of DMEM to maintain hypothalamic tissue viability was assessed, as 
the conditioned medium collected from the BBB cultures to be tested in the 
hypothalamic organotypic cultures was composed of DMEM, differing from the 
appropriate culture medium for the hypothalamic organotypic cultures maintenance, 
the Opti-MEM®. 
The Opti-MEM® was replaced by DMEM supplemented with 10% FBS and 1% P/S 
and the cultures were maintained in a humidified 5% CO2 atmosphere, at 37 ºC for 24 
h. The effect of the treatment on cell viability was assessed by a live/dead assay, 
performed as described in section 2.2.2. 
 
b. Hypothalamic organotypic cultures treatment with plasma 
As a first approach, the ability of systemic factors released after bone injury 
to affect the hypothalamic NPY system activity was assessed through the direct 
incubation of hypothalamic organotypic cultures with plasma collected from animals 
1 day post femur-defect surgery. 
The organotypic cultures were incubated with DMEM with 1% P/S and 10% 
plasma collected from femur-defect animals and from sham-operated and non-
operated animals as controls, as described in 2.4.1. An additional control with DMEM 
supplemented with 10% FBS and 1% P/S was also performed. 
The NPY expression after treatment was assessed by immunohistochemistry, 
following the experimental protocol described in section 2.2.4. 
 
c. In vitro BBB cultures treatment with plasma 
After 11 days of bEnd.3 cells and astrocytes coculture, half of the medium 
from the abluminal side of the transwell filters was replaced by freshly prepared 
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DMEM supplemented with 10% FBS and 1% P/S, and the complete medium of the 
luminal side of the filter was removed and replaced by DMEM supplemented with 1% 
P/S and 10% plasma collected, as described in 2.4.1, from femur-defect and sham-
operated animals at day 1 post-surgery, and from non-operated animals. After 24 h in 
a humidified incubator, the conditioned medium was collected and kept at -80 ºC 
until further experiments. 
 
d. Hypothalamic organotypic cultures treatment with conditioned medium 
from the BBB cultures 
The culture medium of the hypothalamic slice cultures was removed and 
replaced by the conditioned medium collected from the in vitro BBB cultures, as 
described in 2.4.2c. After a 24 h treatment in a humidified 5% CO2 atmosphere at 37 
ºC, the NPY expression was assessed by immunohistochemistry, as described in 2.2.4. 
 
2.5 STATISTICAL ANALYSIS 
  
A one-way ANOVA was used to analyse the data from cell viability in the 
hypothalamic organotypic cultures, and post hoc comparisons were performed using 
Tukey’s test. Data from TEER measurements were analysed using a two-way ANOVA 
(time x culture type), and post hoc comparisons were performed using Tuckey’s test. 
Student’s t-test was used to analyse data from Pe and the DMEM effect in the 
organotypic cultures viability. 
Differences were considered at the significant level of p<0.05. All data are 
expressed as mean ± standard deviation (SD). Statistical analyses were performed 
using the software GraphPad Prism® software (Prism 6 for Windows, CA, USA). 
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To explore whether the circulating factors released after bone injury may 
cross and/or interact with the BBB and modulate the NPY hypothalamic response, 
and due to the complexity of in vivo studies, an in vitro approach was used. To 
address this, two in vitro tools were established, the hypothalamic organotypic 
cultures and the in vitro BBB cultures. 
 
3.1 OPTIMIZATION OF THE HYPOTHALAMIC ORGANOTYPIC CULTURES 
  
 Organotypic cultures are an in vitro culture method that allows the 
preservation of entire organs or fragments of organs during long periods of time, with 
cellular differentiation and organization similar to the microenvironment of origin 
[105]. Over the years, the organotypic slice cultures have been successfully 
established from a variety of brain regions, being widely used for the study of the 
physiological and pharmacological properties of neuronal circuits, mainly in the 
hippocampus [94, 106]. 
In this work, hypothalamic organotypic cultures were established using brains 
from 8-day-old C57Bl/6 mice due to the high degree of plasticity and resistance to 
mechanical trauma of brain tissues at these young ages [106]. At this point, brain 
cytoarchitecture fundamentals are already established and nerve cells are more 
likely to survive explantation [107]. 
 Since the slice preparation causes tissue damage, cultures were maintained 
for 15 days, in order to allow tissue stabilization and recovering of the damaged 
axons to form new neural connections [106]. 
 The functionality of these cultures was evaluated through cell viability, 
presence of neuronal cells in the hypothalamic region and NPY system 
responsiveness. 
 
 3.1.1 Cell viability in the hypothalamic explant 
 The viability of the cultures was assessed through live/dead assays at the end 
of the culture maintenance period, using Calcein AM and PI. Calcein AM stains the 
live cells with green fluorescence while PI stains the dead cells with red 
fluorescence. 
 Initially, slices of 350 μm thickness were used, however, due to the high 
cellular death observed (Fig. 3.1a), different thicknesses were tested, and slices 
with 250 μm showed to result in increased cell viability (Fig. 3.1b). Therefore, 250 
μm thick slices were used in all the experiments. 
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350 μm thickness 250 μm thickness 
  
Figure 3.1: Viability of the hypothalamic organotypic cultures in slices with different thickness. 
Fluorescent micrographs of the tissue viability after 15 days in culture of slices with 350 μm (a) and 250 
μm (b), with Calcein AM staining the live cells (green) and propidium iodide staining the dead cells 
(red) in the hypothalamic region. Scale bar 100 μm. 
 
 The cell viability was followed during the culture maintenance period, at days 
0, 3, 6, 9, 12 and 15 of culture. The obtained results show that, at day 6, the 
percentage of viable cells was higher as compared to days 0 and 3 (Figs. 3.2c and 
3.3), and the tissue reorganization starts to be notorious. At day 15, an organized 
network of viable cells was observed (Fig. 3.2f). 
 Data obtained from the live and dead cell counting showed that the cell 
viability at the end of the culture maintenance period was 82 ± 9.6 %. Moreover, it 
was observed that this value was maintained stable since day 6 (Fig. 3.3), which is in 
accordance with the conclusion drawn from of the observation of the fluorescent 
micrographs. 
 Data analysis reveals a higher percentage of viable cells at days 6, 9, 12 and 
15 of culture when compared to day 0 (p < 0.05, p < 0.01, p < 0.001 and p < 0.001, 
respectively) and day 3 (p < 0.01, p < 0.05 and p < 0.01, respectively) (Fig. 3.3). The 
increase in the number of live cells versus dead cells observed after 6 days of culture 
can be explained by processes of neuro- and gliogenesis, as described to occur in 
hippocampal organotypic cultures [108] and/or by the activity of microglial cells that 
were described to be able to mobilize and engage dead or dying cells in brain slice 
preparations, reducing therefore the number of dead cells and leading to an 
increased percentage of viable cells within the slices [109, 110]. 
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DAY 0 DAY 3 DAY 6 
   
DAY 9 DAY 12 DAY 15 
   
Figure 3.2: Viability of the hypothalamic tissue along the culture period. Fluorescent micrographs of 
the hypothalamic slice culture obtained at days 0, 3, 6, 9, 12 and 15, with Calcein AM staining the live 
cells (green) and propidium iodide staining the dead cells (red). Scale bar 100 μm. 
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Figure 3.3: Statistical analysis of the viability of the hypothalamic tissue along the culture period. 
Percentage of viable cells at culture days 0, 3, 6, 9, 12 and 15. Values are presented as mean ± SD 
(n=3); *p<0.05, **p<0.01, ***p<0.001 used for significant differences from day 0; #p<0.05, ##p<0.01, 
used for significant differences from day 3 (one-way ANOVA).  
 
 In this study, the neurite outgrowth was also used as an indicator of the tissue 
viability. In fact, over the culture time, it was verified an increase in the growth of 
neurites in the extremities of the slices and, at day 15 of culture, an intense neurite 
branching was observed (Fig. 3.4). 
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Figure 3.4: Neurite outgrowth in the hypothalamic organotypic cultures. Fluorescent micrographs of 
the hypothalamic slice culture showing dendritic extensions at the extremities of the slices. Scale bar 
100 μm. 
 
 Tissue reorganization, the increase in the percentage of viable cells and the 
neurite outgrowth support the establishment of viable hypothalamic organotypic 
cultures. 
 
 3.1.2 Presence of neuronal cells in the hypothalamic region 
To further explore the results of the cell viability, the presence of neuronal 
cells within the hypothalamic slices was investigated, through the evaluation of 
NF200 expression, a neuronal marker.  
The obtained data show that cells expressing NF200 are highly abundant, and 
a dense network of neuronal projections was observed in the hypothalamic region 
(Fig. 3.5a). 
Additionally, the presence of astrocytes and microglial cells was evaluated 
through the use of GAFP and Iba-1 cell markers, respectively. The presence of these 
cells in the culture was also confirmed (Fig. 3.5b and c). The moderate number of 
microglial cells within the hypothalamic region suggests that the experimental 
procedure and the culture maintenance are not triggering an intense immune 
response. 
  Hence, the established hypothalamic organotypic cultures showed to allow 
the interaction of the different cell types present in the brain tissue, highly 
mimicking the in vivo conditions. 
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NEURONAL CELLS ASTROCYTES MICROGLIAL CELLS 
   
Figure 3.5: Cell types present in the hypothalamic region. Fluorescent micrographs of the 
hypothalamic slice culture showing the presence of neuronal cells (a, red), astrocytes (b, green) and 
microglial cells (c, green), and counterstained with cell nucleus dye DAPI (blue). Scale bar 100 μm. 
 
 3.1.3 NPY responsiveness 
 After confirming the presence of neuronal cells in the hypothalamic 
organotypic cultures, the ability of these cells to express NPY under stimuli was 
evaluated. A 24 h stimulus with 10-7 M dexamethasone, a glucocorticoid known to 
stimulate the NPY activity [98], was performed at culture day 15. 
As presented in figure 3.6, the NPY expression levels were increased on the 
slices treated with dexamethasone (Fig. 3.6b), when compared to the slices without 
dexamethasone stimuli (Fig. 3.6a), confirming the functionality of the NPYergic 
system in the established culture system. 
 Since the NPY synthesis on the hypothalamus mainly occurs in the neurons of 
the ARC, which are projected to the PVN [111, 112], the ability of the NPY system in 
the ARC to respond to a stimulus, as observed in this study, was essential to validate 
the hypothalamic organotypic cultures established. The obtained data support the 
successful preservation of the neuronal circuitry of this region, enabling the 
assessment of the NPY system activity under different conditions. 
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CONTROL 10-7 M DEXAMETHASONE 
  
Figure 3.6: NPYergic activity in response to a stimulus. Fluorescent micrographs of the hypothalamic 
slices showing the NPY expression at day 15 in the absence (a, NPY staining - red) or in the presence of 
dexamethasone stimulus (b, NPY staining - red), counterstained with cell nucleus dye DAPI (blue). Scale 
bar 100 μm. 
 
3.2 OPTIMIZATION OF THE IN VITRO BBB CULTURES 
  
 To determine the ability of factors released in the injured bone 
microenvironment to cross or interact with the BBB, and subsequently modulate the 
hypothalamic NPY system activity, an in vitro tool that mimics the low and selective 
permeability of the CNS blood vessels was needed. 
 An in vitro model of the BBB was established through a coculture system, 
using primary astrocytes and the bEnd.3 cells, a brain microvascular endothelial cell 
line. 
 The bEnd.3 cells have been widely used for in vitro BBB cultures, due to their 
ability to maintain a BBB phenotype over several passages, to grow easily in culture 
and to form functional barriers [84, 113]. 
 In this study, the functionality of the established model was investigated 
through the evaluation of the astrocytes and bEnd.3 cells phenotype maintenance, 
the TEER and the transendothelial flux. 
 
3.2.1 bEnd.3 cells and astrocytes phenotype 
a. Cell morphology 
The bEnd.3 cells and astrocytes ability to maintain their morphology was 
evaluated after 11 days in culture through F-actin staining in coculture and also in 
monoculture, as a control condition. Both bEnd.3 cells and astrocytes are not 
contact-inhibited cells and the close proximity of the culture conditions increases 
their proliferation rate.  
a b 
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Astrocytes in coculture conditions presented a star-shaped morphology in a 
fairly complete cell layer (Fig. 3.7b), similar to the obtained in monoculture (Fig. 
3.7a), indicating that the astrocytes morphology was not compromised by the 
presence of the endothelial cells.  
The characteristic elongated spindle-shape morphology widely described for 
bEnd.3 cells [114, 115], showing a fibroblastic pattern as observed in monoculture 
(Fig. 3.7c), was also maintained in coculture conditions (Fig. 3.7d). 
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Figure 3.7: Astrocytes and bEnd.3 cells morphology when cultured alone (left panel) or in coculture 
(right panel). Images show fixed and permeabilized astrocytes and bEnd.3 cells grown on collagen type 
IV coated transwell filters, stained with antibody for F-actin when cultured alone (a and c, green) or in 
coculture conditions (b and d, green), and counterstained with cell nucleus dye DAPI (blue). Scale bar 
50 μm. 
 
b. Astrocytes expression of GFAP 
 The ability of astrocytes to maintain the phenotypic characteristics was 
assessed after 11 days in culture, through the expression of GFAP. 
The obtained results show that astrocytes in coculture express GFAP (Fig. 
3.8a) and are phenotypically identical to the astrocytes maintained in monoculture 
(Fig. 3.8b), presenting a fibrillar and cytoplasmic characteristic pattern, as it has 
been reported [84]. 
a b 
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MONOCULTURE COCULTURE 
  
Figure 3.8: Astrocytes expression of GFAP when cultured alone or in the presence of bEnd.3 cells. 
Images show fixed and permeabilized astrocytes grown on collagen type IV coated transwell filters, 
stained with an antibody for GFAP when cultured alone (a, red) or cocultured with bEnd.3 cells (b, 
red), and counterstained with cell nucleus dye DAPI (blue). Scale bar 50 μm. 
 
c. bEnd.3 cells expression of junctional molecules 
To further characterize the bEnd.3 cells phenotype when cultured with 
astrocytes, the presence of characteristic tight and adherens junctions was 
evaluated. 
The expression of the tight junctions markers claudin-5, ZO-1 and occludin, 
and the adherens junctions marker VE-cadherin was assessed. These junctional 
molecules are all well-known to be required for the proper BBB functioning [76, 78, 
84]. Specifically, the tight junctions prevent the passage of large molecules through 
endothelial paracellular diffusion, and the adherens junctions serve to hold 
neighbouring endothelial cells together, contributing for the adequate maintenance 
of the tight junctions and the junctional zone [79, 116]. 
The results obtained showed bEnd.3 cells expression of essential junction 
proteins in the model of the BBB established. In fact, the presence of continuous and 
organized expression of the tight junctional proteins claudin-5 (Fig. 3.9a), ZO-1 (Fig. 
3.9c) and occludin (Fig. 3.9e) was observed in the interendothelial cell contact in 
bEnd.3 cells cultured with astrocytes. The expression of the adherens junctional 
protein VE-cadherin (Fig. 3.9g) was also observed in coculture conditions. 
Additionally, the expression of both tight and adherens junctions in coculture (Fig. 
3.9, right panel) was shown to be identical to the expression observed in 
monoculture conditions (Fig. 3.9, left panel). 
Some diffuse cytoplasmic staining of the markers was observed in the 
endothelial cells, mainly for occludin. Despite being transmembrane proteins, cell 
permeabilization was required for the antibodies recognition of the epitope, which 
may have caused this effect. 
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Figure 3.9: Junction proteins expressed by bEnd.3 cells when cultured alone (left panel) or with 
astrocytes (right panel). Images show fixed and permeabilized bEnd.3 cells grown on collagen type IV 
coated transwell filters and stained with antibodies for claudin-5 (a and b, green), ZO-1 (c and d, red), 
occludin (e and f red) and VE-cadherin (g and h, red), and counterstained with cell nucleus dye DAPI 
(blue). Scale bar 50 μm. 
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 To confirm that all endothelial cells were presenting highly organised tight 
and adherens junctions, without gaps between them, and that, together with 
astrocytes, were mimicking a functional BBB, assays to evaluate the barrier integrity 
were performed, namely the assessment of the TEER and the transendothelial flux. 
 
 3.2.2 In vitro BBB integrity 
In parallel with the qualitative analysis described in 3.2.1, the BBB integrity 
was evaluated by two standard methods: the TEER, which is an indicator of the ion 
conductance across the BBB, and the transendothelial flux, that allows the 
quantification of the paracellular permeability. 
 
a. TEER measurements 
TEER was followed from the second day on of seeding the endothelial cells. 
The results obtained showed that the established culture conditions led to the 
development of reproducibly robust barrier after 11 days in culture.  
At day 2 of culture, the TEER values of the coculture were of 33.3 ± 4.6 Ω x 
cm2, and these values significantly increased thereafter until day 6 (p < 0.05), 
reaching values of 71.1 ± 9.4 Ω x cm2 at day 11 (Fig. 3.10). 
In parallel, the TEER of bEnd.3 cells monoculture was also assessed.  At 
culture day 2, the TEER values were 32.7 ± 1.6 Ω x cm2, similar to the values 
obtained in co-culture conditions. However, the values obtained in monoculture 
conditions were maintained stable, in contrary to the increase observed in the values 
of the co-culture conditions (Fig. 3.10). This confirms the importance of the 
astrocytes in the development of the endothelial cells BBB phenotype. 
The high TEER values in the coculture system suggest that the endothelial 
cells were fully differentiated concerning the establishment of continuous tight and 
adherens junctions. 
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Figure 3.10: TEER values of the in vitro BBB model throughout the 11 days of culture. TEER was 
measured in confluent bEnd.3 cells monoculture and in bEnd.3 cells and astrocytes coculture. TEER was 
monitored following equilibration of the inserts to room temperature using the Millicell® ERS-2. Values 
are presented as mean ± SD (n=6). *p < 0.05, **** p < 0.0001 used for, at the same time point, 
significant differences from monoculture; ####p < 0.0001 used for, in coculture, significant difference 
from day 2; ++++p < 0.0001 used for, in coculture, significant difference from day 4; ∆p < 0.05 used for, 
in coculture, significant difference from day 6 (two-way ANOVA). 
 
b. Permeability measurement 
To further explore the integrity of the in vitro BBB, the paracellular 
permeability to Fluorescein sodium salt (376 Da) was assessed. Fluorescein was 
chosen for having a smaller size relatively to the range of possible candidates for 
circulating factors, which may have from 400 to 500 Da.  
The obtained results showed Pe values for the coculture system averaging 3.3 
x 10-6 ± 1.1 x 10-7 cm/sec. Moreover, these values were lower when comparing to the 
obtained in bEnd.3 cells monoculture (p < 0.01), which presented Pe values averaging 
4.3 x 10-6 ± 1.9 x 10-7 cm/sec. 
Pe values within the 10-6 range were described as indicative of the 
establishment of a highly developed in vitro BBB [83, 113]. Thus, the Pe values 
obtained confirm the reduced paracellular permeability of this in vitro BBB model. 
Moreover, the significant differences observed between the coculture and 
monoculture Pe values reinforce the importance of the astrocytes in the 
development of a functional barrier. 
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Figure 3.11: Permeability coefficients of the in vitro BBB model at day 11 of monoculture and 
coculture. Pe to Fluorescein were assessed in confluent bEnd.3 cells monoculture and in bEnd.3 cells 
and astrocytes coculture. Values are presented as mean ± SD (n=3). **p < 0.01 (Students’ t-test). 
 
In summary, the in vitro BBB model established is characterized by high TEER 
values and low paracellular permeability to small molecules. These results are in 
agreement with the data obtained from the characterization of the cell phenotype, 
suggesting the establishment of functional tight and adherens junctions, and 
confirming this model as a valuable tool for mimicking the BBB.  
 
3.3 HYPOTHALAMIC NPYERGIC RESPONSE TO SYSTEMIC FACTORS RELEASED 
AFTER BONE INJURY 
  
 The optimization of the in vitro BBB and the hypothalamic organotypic 
cultures allowed to test the initial hypothesis of this study: are the circulating 
factors released from injured bone microenvironment able to cross and/or interact 
with the BBB and modulate the NPY hypothalamic response? 
 To address this hypothesis, the in vitro BBB cultures were incubated with 
plasma collected from animals with femur-defect, the resulting conditioned medium 
was collected and used to treat the hypothalamic organotypic cultures, and the NPY 
system response was assessed. Data was compared with results from experiments 
performed with plasma from sham-operated and non-operated animals.  
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 3.3.1 Hypothalamic tissue viability cultured with DMEM 
 A correct interpretation of the hypothalamic NPY response depends on the 
ensured tissue viability.  
 Before proceeding to the treatment of the hypothalamic slices with the 
conditioned medium from the BBB cultures a major setback had to be surpassed. At 
this point it was necessary to evaluate the ability of DMEM to maintain the 
hypothalamic tissue viability, as the culture medium collected from in vitro BBB 
model to be tested in the hypothalamic organotypic cultures is composed of DMEM 
and different from the medium used in the maintenance of the hypothalamic 
organotypic cultures, the Opti-MEM®. 
 After 24 h of incubation with DMEM, the tissue viability was assessed through 
a live/dead assay with Calcein AM and PI. It was observed that DMEM did not 
significantly impact the cell viability (Fig. 3.12a and b), as the percentage of living 
cells, averaging 72.0 ± 5.8 %, was not significantly different from the values obtained 
with the appropriate culture medium of the hypothalamic organotypic cultures (82 ± 
9.7 %) (Fig. 3.12c). 
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Figure 3.12: Hypothalamic tissue viability when cultured with DMEM. Fluorescent micrograph of the 
hypothalamic slice culture obtained at day 15 with Opti-MEM® (a) and after a 24 h incubation with 
DMEM (b). Calcein AM stains the live cells (a and b, green) and propidium iodide stains the dead cells (a 
and b, red). Percentage of living cells in when cultured with Opti-MEM® and DMEM (c). Values are 
presented as mean ± SD (n=3); ns: non-significant (Students’ t-test). Scale bar 100 μm. 
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 3.3.2 NPY expression on hypothalamic slices directly treated with plasma 
from femur-injured mice 
 As a first approach, the effect of circulating factors that were released in the 
injured bone microenvironment on the NPY system activity was assessed, by directly 
treating the hypothalamic slices with the plasma. 
 The obtained results showed that the NPY expression levels were increased in 
the slices treated with plasma collected from femur-defect animals (Fig. 3.13d) 
when compared to the levels after stimuli with plasma from sham-operated and non-
operated animals (Fig. 3.13b and c). Despite this, the difference in the NPY levels 
between the slices treated with plasma of femur-defect and sham-operated animals 
was less expressive. 
 These data suggests that, in fact, factors present in plasma and probably 
associated with bone defect have the ability to modulate the NPY system activity in 
the hypothalamus. However, the major challenge is to understand if these factors 
have the ability to cross or interact with the BBB, and subsequently modulate the 
NPY system activity. 
CONTROL WITH FBS NON-OPERATED 
  
SHAM-OPERATED FEMUR-DEFECT 
  
Figure 3.13: NPYergic activity in response to the treatment with plasma. Fluorescent micrographs of 
the hypothalamic organotypic cultures showing the NPY expression (red) after treatment with culture 
medium with FBS (a), with plasma collected from non-operated animals (b), sham-operated (c) and 
femur-defect animals (d), counterstained with cell nucleus dye DAPI (blue). Scale bar 100 μm. 
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 3.3.3 NPY expression by the hypothalamic organotypic cultures treated 
with conditioned medium from the in vitro BBB cultures 
 The NPY hypothalamic activity in organotypic slices treated with conditioned 
medium from the in vitro BBB cultures was assessed by immunohistochemistry. The 
conditioned medium was composed by the circulating factors released after bone 
injury that were able to cross the BBB and by factors eventually produced by the 
interaction of the plasma with this barrier. 
 The NPY response was shown to be increased after treatment with 
conditioned medium collected from in vitro BBB cultures treated with plasma from 
femur-defect animals (Fig. 3.14d), when compared to the treatment with 
conditioned medium from in vitro BBB cultures treated with plasma from non-
operated animals (Fig. 3.14b). However, no differences were observed in the NPY 
expression between slices treated with conditioned medium collected from in vitro 
BBB cultures cultured with plasma from femur-defect and from sham-operated 
animals (Fig. 3.14c). 
CONTROL WITH FBS NON-OPERATED 
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Figure 3.14: NPYergic activity in response to the treatment with conditioned medium collected 
from the in vitro BBB cultures. Fluorescent micrographs of the hypothalamic organotypic cultures 
showing the NPY expression (red) on cultures treated with conditioned medium with FBS (a), and with 
plasma collected from non-operated animals (b), sham-operated (c) and femur-defect animals (d), 
counterstained with cell nucleus dye DAPI (blue). Scale bar 100 μm. 
a b 
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 These data indicate that molecules within the plasma from femur-defect and 
sham-operated animals are able to cross and/or interact with the BBB, and modulate 
the hypothalamic NPY system activity. However, it was not possible during this study 
to specifically correlate the effects of these systemic factors with the presence of a 
femur-defect, as both plasmas from femur-defect and sham operated animals induce 
a similar increase in the hypothalamic NPY expression. Therefore, these results may 
suggest that the increase in the NPY expression levels could be associated with a 
common process occurring in both femur and sham-operated animals and, at the 
time point in study, the inflammation presents as the putative common process 
responsible for this effect in the hypothalamic NPY system activity. 
 The role of the circulating factors that, by crossing and/or interacting with 
the BBB, may modulate the hypothalamic NPY system activity needs to be further 
explored. Specifically, testing different plasma and conditioned medium 
concentrations will allow to determine whether the response of the NPY system is 
not being compromised. In fact, the NPY capacity to respond to stimuli might be 
overtaken by the actual formulation of the plasma and conditioned medium, 
preventing the detection of differences in the NPY expression levels. 
 Also, the use of techniques such as the assessment of the mRNA expression, 
and the specific protein quantification by western blot would allow a quantitative 
analysis of the hypothalamic NPY expression levels. This approach may permit the 
detection of differences between the NPY activity in response to conditioned 
mediums from femur-defect and sham-operated animals and, thereby, allowing to 
clarify the qualitative analysis given by the immunostaining tests performed in this 
study. 
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In the present study an in vitro approach was used to explore the role of the 
humoral pathway in the feedback loop from injured bone to the hypothalamic NPY 
system. 
Organotypic slice culture systems have been extensively studied from a 
variety of brain regions including hippocampus, striatum, spinal cord and cerebellum, 
due to their ability to replicate many aspects of the in vivo context. In the present 
work, organotypic cultures of the hypothalamus were successfully established. The 
optimized culture conditions promoted high tissue viability and, importantly for the 
purposes of this study, the preservation of the NPY system responsiveness was 
achieved. 
A functional model mimicking the BBB was also successfully established, 
through a coculture system using endothelial cells and astrocytes. The optimal 
conditions to maintain the cell phenotype and the integrity of the barrier were 
settled. This coculture system promoted the maintenance of the brain 
microvasculature phenotype of the endothelial cells, as demonstrated by the 
expression of BBB characteristic junctional molecules, successfully replicating the 
high restrictiveness of the BBB and its low paracellular permeability. 
The combination of these two in vitro systems allowed the establishment of a 
suitable platform to investigate the mechanisms underlying the communication 
between the peripheral systems and the CNS through a humoral pathway, specifically 
the communication between injured bone and the NPY hypothalamic system. 
The first results obtained using this experimental set-up suggest that 
molecules within the plasma collected from femur-defect and sham-operated animals 
are able to cross and/or interact with the BBB and subsequently increase the NPY 
hypothalamic system activity. The findings obtained so far do not allow to correlate 
the modulation of the NPY activity by systemic factors with the presence of a bone 
defect, since no differences were detected between the NPY expression in response 
to the conditioned medium from femur-defect and sham-operated animals. 
Therefore, the increased NPY expression levels observed could be related with 
common processes that are occurring in both femur-defect and sham-operated 
animals. In this scenario, inflammation presents as the putative common process. 
Hence, the role of the humoral pathway in the modulation of the NPY system activity 
has to be further explored. 
 As future work, to clarify the role of the systemic factors released in the 
injured bone microenvironment in the modulation of the hypothalamic NPY system 
response, different concentrations of plasma and conditioned medium will be tested, 
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in order to understand whether the NPY system activity is not being compromised by 
the actual formulation of plasma and conditioned medium. Techniques such as the 
mRNA expression and western blot will be used to quantify the NPY response, which 
may allow to detect differences between undetectable by the immunostaining tests 
performed. The identification of the factors that are modulating the NPY system 
response will be also assessed. Moreover, the effects of the circulating factors in the 
expression of the Y2R, a NPY receptor known to be involved in the hypothalamic 
regulation of bone physiology and shown to be affected after bone injury in our in 
vivo studies, will be also investigated. 
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